Rockwell Medical, Inc. (RMTI) — SEC Filings

Rockwell Medical, Inc. (RMTI) — 29 SEC filings. Latest: 8-K (May 7, 2026). Includes 15 8-K, 6 10-Q, 3 10-K.

View Rockwell Medical, Inc. on SEC EDGAR

Overview

Rockwell Medical, Inc. (RMTI) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a ARS filed on Apr 30, 2026: Rockwell Medical, Inc. filed its Annual Report to Security Holders (ARS) on April 30, 2026, for the period ending December 31, 2025. The company is located at 30142 Wixom Road, Wixom, MI 48393. The filing is a standard annual report and does not contain specific financial figures or significant even

Sentiment Summary

Across 29 filings, the sentiment breakdown is: 1 bullish, 2 bearish, 25 neutral, 1 mixed. The dominant filing sentiment for Rockwell Medical, Inc. is neutral.

Filing Type Overview

Rockwell Medical, Inc. (RMTI) has filed 15 8-K, 1 ARS, 3 10-K, 6 10-Q, 2 DEF 14A, 2 SC 13G/A with the SEC between Jan 2024 to May 2026.

Filings by Year

2026 · 2025 · 2024

Recent SEC Filings (29)

Rockwell Medical, Inc. SEC Filing History
DateFormDescriptionRisk
May 7, 20268-K8-K Filing
Apr 30, 2026ARSRockwell Medical Files Annual Reportlow
Mar 26, 20268-KRockwell Medical Files 8-K with Investor Presentation
Mar 26, 202610-KRockwell Medical Expands Product Line, Secures Key Deals in Growth-Focused 2025medium
Mar 26, 20268-KRockwell Medical Files 8-K on Q4/FY Earnings
Nov 18, 20258-KRockwell Medical Announces Executive and Board Changesmedium
Nov 12, 202510-QRockwell Medical Plunges to $4.76M Loss Amidst Sales Slumphigh
Sep 29, 20258-KRockwell Medical Announces Executive and Board Changesmedium
Aug 14, 202510-QRockwell Medical Sales Plummet, Swings to Loss Amid Macro Headwindshigh
May 20, 20258-KRockwell Medical Files 8-K for Security Holder Votelow
May 12, 20258-KRockwell Medical, Inc. Files 8-K on Financialslow
May 12, 202510-QRockwell Medical Files Q1 2025 10-Qmedium
Apr 14, 2025DEF 14ARockwell Medical Files 2025 Proxy Statementlow
Mar 20, 20258-KRockwell Medical Files 8-K with Financial Updateslow
Mar 20, 202510-KRockwell Medical Files 2024 10-Kmedium
Dec 12, 20248-KRockwell Medical Appoints New CMO, Elects Directorsmedium
Nov 14, 2024SC 13G/ASC 13G/A Filing
Nov 13, 20248-KRockwell Medical Files 8-K: Other Events & Financialslow
Nov 12, 202410-QRockwell Medical Files Q3 2024 10-Qmedium
Aug 8, 202410-QRockwell Medical Files Q2 2024 10-Qmedium

Risk Profile

Risk Assessment: Of RMTI's 21 recent filings, 2 were flagged as high-risk, 10 as medium-risk, and 9 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Key Executives

  • Heather Hunter
  • Rashad Brown
  • Joe Dawson
  • Dr. Robert L. Johnson
  • Ms. Sarah Chen
  • Dr. Robert L. Judd
  • Ms. Karen L. King
  • Mr. David M. D. Smith

Industry Context

Rockwell Medical operates within the U.S. hemodialysis concentrates market, which is experiencing steady growth, projected to increase from $450 million in 2024 to $560 million by 2028. This market is characterized by the critical need for reliable and safe dialysis solutions for patients with end-stage kidney disease. Key players supply essential concentrates and related products to a network of dialysis centers and providers.

Top Tags

10-Q (4) · Hemodialysis (3) · Medical Devices (3) · management-change (3) · corporate-governance (3) · financials (3) · annual-report (2) · Operational Efficiency (2) · 8-K (2) · board-of-directors (2)

Key Numbers

Rockwell Medical, Inc. Key Metrics
MetricValueContext
Period of Report2025-12-31The end date for the reporting period covered by the ARS.
Filing Date2026-04-30The date Rockwell Medical, Inc. submitted this ARS filing.
Aggregate market value of nonvoting common equity held by nonaffiliates$28,688,982as of June 30, 2025
Shares outstanding of Common Stock39,405,302as of March 23, 2026
Projected U.S. hemodialysis concentrates market size$560 millionby 2028, up from $450 million in 2024
New customers added in the western U.S.30in Q4 2025, increasing western U.S. footprint to over 10%
Total customers294including all five leading U.S. dialysis providers
Size of new single-use bicarbonate cartridge720 gramsone of two sizes introduced in February 2025
Individual purchasing facilities in the U.S.12,000market opportunity for Rockwell Medical
Year DaVita agreement extended to2026through December 31, 2026, with increased product pricing
Year manufacturing concluded at South Carolina facility2025in the third quarter, for operational streamlining
Net Sales$50.912MDecreased from $76.824M for the nine months ended September 30, 2024
Net Loss$(4.760)MCompared to net income of $0.276M for the nine months ended September 30, 2024
Net Cash Used In Operating Activities$(2.950)MFor the nine months ended September 30, 2025, compared to $3.337M provided in 2024
Cash and Cash Equivalents$13.610MAs of September 30, 2025, down from $15.662M at December 31, 2024

Related Companies

RMED

Frequently Asked Questions

What are the latest SEC filings for Rockwell Medical, Inc. (RMTI)?

Rockwell Medical, Inc. has 29 recent SEC filings from Jan 2024 to May 2026, including 15 8-K, 6 10-Q, 3 10-K. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of RMTI filings?

Across 29 filings, the sentiment breakdown is: 1 bullish, 2 bearish, 25 neutral, 1 mixed. The dominant sentiment is neutral.

Where can I find Rockwell Medical, Inc. SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Rockwell Medical, Inc. (RMTI) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Rockwell Medical, Inc.?

Key financial highlights from Rockwell Medical, Inc.'s most recent 10-K include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.

What is the investment thesis for RMTI?

The investment thesis for RMTI includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Rockwell Medical, Inc.?

Key executives identified across Rockwell Medical, Inc.'s filings include Heather Hunter, Rashad Brown, Joe Dawson, Dr. Robert L. Johnson, Ms. Sarah Chen and 3 others.

What are the main risk factors for Rockwell Medical, Inc. stock?

Of RMTI's 21 assessed filings, 2 were flagged high-risk, 10 medium-risk, and 9 low-risk.

What are recent predictions and forward guidance from Rockwell Medical, Inc.?

Forward guidance and predictions for Rockwell Medical, Inc. are extracted from SEC filings as they are enriched.

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.